Login | Users Online: 609  
Home Print this page Email this page Small font sizeDefault font sizeIncrease font size   
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contact us
Year : 2020  |  Volume : 21  |  Issue : 1  |  Page : 6-16

Discovering novel biochemical and genetic markers for coronary heart disease in Qatari individuals: The initiative Qatar cardiovascular biorepository

1 Department of Clinical Medicine, Weill Cornell Medical College; Department of Surgery, Clinical Research, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
2 Department of Adult Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
3 Department of Laboratory Medicine and Pathology, Molecular Genetics Laboratory, Hamad Medical Corporation, Doha, Qatar
4 Academic Health System, Translational Research Laboratory Institute, Hamad Medical Corporation, Doha, Qatar
5 Department of Cardiovascular Diseases and The Gonda Vascular Center, Mayo Clinic, Rochester, MN, USA

Correspondence Address:
Dr. Jassim Al Suwaidi
Department of Adult Cardiology, Heart Hospital, Hamad Medical Corporation, P.O Box 3050, Doha
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and Permissions

Background: We aimed to describe the creation and challenge of a DNA and plasma biorepository (Qatar Cardiovascular Biorepository) with linkage to the electronic health record of cardiovascular risk factors to facilitate discovery of novel genetic and proteomic biomarkers for coronary heart disease in Qatari individuals. Methods: A prospective case–control study was conducted between October 2013 and February 2018. CHD was defined as a history of an acute coronary syndrome (myocardial infarction [MI]/unstable angina) or coronary revascularization. Controls were identified from blood donors who had no history of coronary heart diesase. After informed consent, blood samples were obtained for DNA and plasma. Demographic, laboratory, and clinical variables were derived from the electronic medical record, and information regarding history of cardiovascular diseases and risk factors was collected from surveys. Challenges in establishing the biorepository were noted, and processes to promote use of the biorepository by Qatari investigators were put in place. Results: During the study period, 2671 individuals were approached; of them, 2087 participants were recruited (1029 patients and 1058 controls). Relevant risk factors were ascertained from the electronic health record and surveys. The mean age was 49 ± 16 years, with 61% males. Challenges included setting up the infrastructure for qatar cardiovascular biorepository, developing an informed consent document in Arabic/English, and meeting target recruitment goals. The prevalence of diabetes mellitus, hypertension, dyslipidemia, and smoking was 41%, 44.5%, 40%, and 19%, respectively. History of myocardial infarction, percutaneous coronary intervention, and coronary artery bypass surgery was 55%, 68%, and 17%, respectively, among patients. Conclusions: This study addresses the challenges in setting up qatar cardiovascular biorepository, the first cardiovascular genomics biorepository in the Arab Middle Eastern region. QCBio is a unique resource for identifying genetic susceptibility variants and novel circulating markers for coronary heart disease in Qatari adults and enables individualized assessment of risk for coronary heart disease.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded96    
    Comments [Add]    

Recommend this journal